Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 100
- Avg volume
- —
- Day's range
- $2.10 – $2.10
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriu...
Show more
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism, which has completed phase 3 clinical trial. It has strategic collaboration agreements with Shanghai Pharmaceutical, XtalPi, Anke Bio, and the United Family Healthcare. VISEN Pharmaceuticals was incorporated in 2018 and is headquartered in Suzhou, China.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Website
- https://www.visenpharma.com/cn
- Address
- Building B, Hengtai Lixiang Chuangxin Tower, Suite 3-108, Floor 3 69 Jiuzhang Road Wuzhong District, Suzhou, China
Latest news
No headlines yet.
